drugset / Trial / NCT03007693

A Study to Investigate Safety and Tolerability, Pharmacokinetics and Pharmacodynamics of JNJ 61393215 in Healthy Participants

NCT03007693 ↗

Phase 1 Completed 71 enrolled Janssen Research & Development, LLC
RandomizedSingle-groupDouble-blindOther

Summary

The purpose of this study is to investigate the safety and tolerability of JNJ-61393215 after multiple consecutive dose administrations and to characterize the pharmacokinetics (PK) of JNJ-61393215 in plasma after multiple consecutive dose administrations.

Timeline

Start
2017-01
Primary completion
2017-10
Completion
2017-10

Drugs

EvaluationDrugModalityDoseRoute
Subject TEBITOREXANT Small molecule — —

Indications

No indication recorded.